Jundishapur Journal of Microbiology

Published by: Kowsar

A Study on the Virus-Like Particle Formation of Hepatitis E Virus ORF2 and Rotavirus NSP4 Protein in the Eukaryotic and Prokaryotic Expression Systems

Manoochehr Makvandi 1 , Ali Teimoori 1 , 2 , Niloofar Neisi 1 , * and Alireza Samarbafzadeh 1
Authors Information
1 Infectious and Tropical Diseases Research Center, Health Research Institute, Department of Virology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2 Research Center for Infectious Diseases of Digestive System, Imam Khomeini hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Article information
  • Jundishapur Journal of Microbiology: December 2017, 10 (12); e57671
  • Published Online: November 21, 2017
  • Article Type: Research Article
  • Received: August 9, 2017
  • Revised: October 6, 2017
  • Accepted: October 14, 2017
  • DOI: 10.5812/jjm.57671

To Cite: Makvandi M, Teimoori A, Neisi N, Samarbafzadeh A. A Study on the Virus-Like Particle Formation of Hepatitis E Virus ORF2 and Rotavirus NSP4 Protein in the Eukaryotic and Prokaryotic Expression Systems, Jundishapur J Microbiol. 2017 ; 10(12):e57671. doi: 10.5812/jjm.57671.

Abstract
Copyright © 2017, Jundishapur Journal of Microbiology. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
6. Conclusions
Acknowledgements
Footnotes
References
  • 1. Li S, Zhang J, Xia N. Lessons from hepatitis E vaccine design. Curr Opin Virol. 2015; 11: 130-6[DOI][PubMed]
  • 2. Li TC, Suzaki Y, Ami Y, Dhole TN, Miyamura T, Takeda N. Protection of cynomolgus monkeys against HEV infection by oral administration of recombinant hepatitis E virus-like particles. Vaccine. 2004; 22(3-4): 370-7[DOI][PubMed]
  • 3. Noad R, Roy P. Virus-like particles as immunogens. Trends Microbiol. 2003; 11(9): 438-44[DOI][PubMed]
  • 4. Zhao Q, Li S, Yu H, Xia N, Modis Y. Virus-like particle-based human vaccines: quality assessment based on structural and functional properties. Trends Biotechnol. 2013; 31(11): 654-63[DOI][PubMed]
  • 5. Kushnir N, Streatfield SJ, Yusibov V. Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine. 2012; 31(1): 58-83[DOI][PubMed]
  • 6. Li TC, Takeda N, Miyamura T, Matsuura Y, Wang JC, Engvall H, et al. Essential elements of the capsid protein for self-assembly into empty virus-like particles of hepatitis E virus. J Virol. 2005; 79(20): 12999-3006[DOI][PubMed]
  • 7. Kamili S. Toward the development of a hepatitis E vaccine. Virus Res. 2011; 161(1): 93-100[DOI][PubMed]
  • 8. Aguilar JC, Rodriguez EG. Vaccine adjuvants revisited. Vaccine. 2007; 25(19): 3752-62[DOI][PubMed]
  • 9. Tagliabue A, Rappuoli R. Vaccine adjuvants: the dream becomes real. Hum Vaccin. 2008; 4(5): 347-9[DOI][PubMed]
  • 10. Gupta RK, Siber GR. Adjuvants for human vaccines--current status, problems and future prospects. Vaccine. 1995; 13(14): 1263-76[DOI][PubMed]
  • 11. Kavanagh OV, Ajami NJ, Cheng E, Ciarlet M, Guerrero RA, Zeng CQ, et al. Rotavirus enterotoxin NSP4 has mucosal adjuvant properties. Vaccine. 2010; 28(18): 3106-11[DOI][PubMed]
  • 12. Ball JM, Mitchell DM, Gibbons TF, Parr RD. Rotavirus NSP4: a multifunctional viral enterotoxin. Viral Immunol. 2005; 18(1): 27-40[DOI][PubMed]
  • 13. Zhang J, Liu CB, Li RC, Li YM, Zheng YJ, Li YP, et al. Randomized-controlled phase II clinical trial of a bacterially expressed recombinant hepatitis E vaccine. Vaccine. 2009; 27(12): 1869-74[DOI][PubMed]
  • 14. Makvandi M, Teimoori A, Neisi N, Samarbafzadeh A. Designing, Construction and Expression of a Recombinant Fusion Protein Comprising the Hepatitis E Virus ORF2 and Rotavirus NSP4 in the Baculovirus Expression System. Jundishapur J Microbiol. 2016; 9(11)[DOI][PubMed]
  • 15. Oliver S. Proteins and proteomics: A laboratory manual. Nature. 2003; 422(6931): 473[DOI]
  • 16. Li SW, Zhang J, He ZQ, Gu Y, Liu RS, Lin J, et al. Mutational analysis of essential interactions involved in the assembly of hepatitis E virus capsid. J Biol Chem. 2005; 280(5): 3400-6[DOI][PubMed]
  • 17. Roy P, Noad R. Virus-like particles as a vaccine delivery system: myths and facts. Adv Exp Med Biol. 2009; 655: 145-58[DOI][PubMed]
  • 18. Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol. 2004; 82(5): 488-96[DOI][PubMed]
  • 19. Holmgren J, Czerkinsky C, Eriksson K, Mharandi A. Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine. 2003; 21 Suppl 2-95[DOI][PubMed]
  • 20. Zhang M, Zeng CQ, Dong Y, Ball JM, Saif LJ, Morris AP, et al. Mutations in rotavirus nonstructural glycoprotein NSP4 are associated with altered virus virulence. J Virol. 1998; 72(5): 3666-72[PubMed]
  • 21. Niikura M, Takamura S, Kim G, Kawai S, Saijo M, Morikawa S, et al. Chimeric recombinant hepatitis E virus-like particles as an oral vaccine vehicle presenting foreign epitopes. Virology. 2002; 293(2): 273-80[DOI][PubMed]
  • 22. Jariyapong P, Xing L, van Houten NE, Li TC, Weerachatyanukul W, Hsieh B, et al. Chimeric hepatitis E virus-like particle as a carrier for oral-delivery. Vaccine. 2013; 31(2): 417-24[DOI][PubMed]
  • 23. Li T, Takeda N, Miyamura T. Oral administration of hepatitis E virus-like particles induces a systemic and mucosal immune response in mice. Vaccine. 2001; 19(25-26): 3476-84[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments